Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder
September 21, 2022 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
VistaGen logo FINAL.png
VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
March 24, 2022 08:00 ET | VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to...
VistaGen logo FINAL.png
VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
February 10, 2022 16:20 ET | VistaGen Therapeutics, Inc.
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD)...
VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
November 16, 2021 08:30 ET | VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of...
VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
November 10, 2021 16:20 ET | VistaGen Therapeutics, Inc.
PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan PH94B Phase 2A clinical program...
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
October 14, 2021 08:00 ET | VistaGen Therapeutics, Inc.
Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3...